Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing–Remitting Multiple Sclerosis: A Cohort Study

Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing–Remitting Multiple Sclerosis: A Cohort Study

The objective of this study was to evaluate the clinical files of patients with RRMS who started rituximab (RTX) compared with a second-line treatment (natalizumab (NTZ) or fingolimod (FTY)). This was a historical cohort study. We compared the effect according to the Expanded Disability Status Scale...

Full description

Bibliographic Details
Main Authors: Martha Rocio Hernández-Preciado, Jazmin Marquez-Pedroza, Nayeli Alejandra Sánchez-Rosales, José de Jesús García-Rivera, Antonio Kobayashi-Gutiérrez, Blanca Miriam Torres-Mendoza, Efraín Chavarría-Avila, Raúl Alejandro Montaño-Serrano, Fernando Cortes-Enriquez, Mario Alberto Mireles-Ramírez
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Journal of Clinical Medicine
Subjects:
multiple sclerosis
relapsing–remitting
rituximab
Online Access:https://www.mdpi.com/2077-0383/11/13/3584

Similar Items

Similar Items